Perrigo Q1 2026 slides: EPS beats amid market softness, shares gain

Perrigo beat Q1 adjusted EPS estimates at $0.43 versus $0.33, though revenue missed at $969M versus $1.03B expected and core net sales fell 8.3% year over year. Shares rose 4.73% premarket as investors focused on margin resilience, strategic progress on the Three-S plan, and reaffirmed 2026 guidance of $2.25 to $2.55 in core adjusted EPS. Management expects a second-half recovery, with full-year core operating margin guided to 15.0% to 16.0%.

Analysis

PRGO is a classic “bad tape, decent print” setup: the market is pricing the first-quarter demand air pocket as if it were structural, while management is signaling a more normal second half plus an unusually levered operating rebound. The key second-order effect is that a low fixed-cost base means even modest recovery in seasonal categories can create outsized margin expansion, so the main driver of earnings revisions is not revenue growth but mix, factory utilization, and the pace at which cost saves flow through.

The setup is also more interesting on capital structure than on consumer demand. The divestiture cash, refinancing activity, and lack of near-term maturities reduce balance-sheet risk enough that the equity increasingly trades like a self-help turnaround rather than a stressed balance-sheet story; that tends to compress downside unless the operating plan stumbles. The market may be underestimating how much of the valuation is now hostage to execution on the Operational Enhancement Program rather than the OTC category itself.

Competition-wise, weaker category conditions hurt smaller store-brand suppliers with less distribution leverage, while Perrigo can use retailer relationships and innovation slots to defend shelf space. If the company keeps taking share in NRT and allergy, the more durable implication is not just higher sales, but better retailer dependence and more favorable assortment economics into 2027. That said, the biggest near-term risk is that the first-half seasonal miss becomes a “confidence tax” and prevents the stock from rerating until Q3 evidence arrives.

Consensus likely underweights how asymmetrical this is from here: the downside is bounded by asset-sale proceeds, dividend support, and deleveraging, while the upside is a 2H margin step-up if utilization normalizes and innovation lands on schedule. The market is effectively paying for no execution, but the multiple can expand quickly if management simply proves the second-half bridge is real. The real tell will be whether the company can hold share while gross margin inflects back above 40% on a core basis.

Key Decisions for Investors

• Long PRGO for a 3-6 month recovery trade: target the 2H guidance reset and margin inflection; upside is meaningful if the market believes the EPS bridge, while downside is cushioned by balance-sheet improvements and the dividend.
• Buy PRGO Jan-2027 calls / call spreads to express the self-help rerating with limited capital at risk; the best payoff comes if 2026 guidance is merely met and 2027 becomes the new debate.
• Pair long PRGO vs short a higher-multiple OTC/consumer staples name with more cyclical exposure to seasonal demand (e.g., long PRGO / short CHD or KMB on relative valuation), betting execution and deleveraging matter more than top-line growth in the next two quarters.
• If entering ahead of Q2/Q3 prints, hedge with a small short or put spread into the next earnings date: this is a credibility story, and a single miss on inventory or margin can re-open the de-rating quickly.
• For income-oriented accounts, use PRGO as a high-yield special situation only if comfortable with operational volatility; the stock offers attractive carry, but the cleaner risk/reward is in options rather than outright yield capture.